Stockreport

Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine

Zosano Pharma Corporation  (ZSAN) 
Last zosano pharma corporation earnings: 11/9 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.zosanopharma.com
PDF 41.5% of patients experienced freedom from pain at 2 hours vs. 14.3% for placebo (p 68.3% of patients experienced freedom from most bothersome symptom at 2 hours vs. [Read more]